The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Severe Asthma — Biologic Treatment Selection Algorithm (T2-High vs T2-Low Endotype)

Evidence-based decision algorithm for selecting biologic therapy in severe uncontrolled asthma based on inflammatory endotype and biomarkers (blood eosinophils, FeNO, total and specific IgE), comorbidities (CRSwNP, atopic dermatitis, EGPA), and disease characteristics; covers all six FDA-approved asthma biologics — omalizumab (anti-IgE), mepolizumab/reslizumab (anti-IL-5), benralizumab (anti-IL-5R), dupilumab (anti-IL-4Rα), tezepelumab (anti-TSLP) — with selection priorities, switching strategies, and treat-to-target approach.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Severe Asthma — Biologic Treatment Selection Algorithm (T2-High vs T2-Low Endotype)?

Severe asthma is a heterogeneous condition affecting 5–10 percent of asthma patients but accounts for 50 percent of asthma-related healthcare costs and significant morbidity. Per ERS/ATS 2014 and GINA 2023 definitions, severe asthma requires confirmed asthma diagnosis plus: (a) treatment with high-dose inhaled corticosteroids (ICS) combined with second controller (long-acting β2-agonist [LABA], long-acting muscarinic antagonist [LAMA], leukotriene receptor antagonist [LTRA], or theophylline) and/or oral corticosteroids ≥50 percent of previous year for control, AND (b) uncontrolled asthma despite this treatment defined as poor symptom control (Asthma Control Test ACT <20 or Asthma Control Questionnaire ACQ ≥1.5), or frequent severe exacerbations (≥2 per year requiring oral corticosteroids), or serious exacerbations (≥1 per year requiring hospitalization, ICU, or mechanical ventilation), or persistent airflow obstruction (post-bronchodilator FEV1 <80 percent predicted with reduced FEV1/FVC ratio).

Asthma is now recognized as heterogeneous syndrome with distinct endotypes (mechanistic disease subtypes) and phenotypes (clinical presentations). Major endotype framework: (1) Type 2 high (T2-high) asthma — characterized by Th2 cytokine inflammation (IL-4, IL-5, IL-13), eosinophilic airway inflammation, elevated FeNO (fractional exhaled nitric oxide), elevated blood and sputum eosinophils, atopic background with elevated IgE and aeroallergen sensitization in some, periostin elevation, mucus hypersecretion; subtypes — early-onset allergic asthma (childhood-onset, atopic, exercise-induced, allergen-driven), late-onset eosinophilic asthma (adult-onset, less atopic, severe with frequent exacerbations, often with CRSwNP and AERD/Samter's triad); (2) Type 2 low (T2-low) asthma — neutrophilic or paucigranulocytic inflammation, less responsive to corticosteroids, often associated with smoking, infection, obesity, occupational exposure; subtypes — neutrophilic, paucigranulocytic, mixed.

Biomarkers for endotyping: (a) Blood eosinophils — most accessible, performed routinely; counts in cells/μL; cutoffs vary by indication: ≥150, ≥300, ≥400, ≥500 used; reflects T2 inflammation but variable day-to-day; affected by oral steroids (suppression), parasitic infection (elevation), other conditions; (b) Fractional exhaled nitric oxide (FeNO) — reflects IL-13-driven epithelial inflammation; cutoffs: <25 ppb (low), 25–50 (intermediate), >50 (high); useful with eosinophil count for T2 inflammation assessment; affected by ICS use (decrease), smoking (decrease), age, allergic rhinitis (increase); (c) Total serum IgE — for omalizumab dosing; range 30–700 IU/mL (extended to 1500 IU/mL with body weight tables); aeroallergen-specific IgE for allergic asthma confirmation; (d) Sputum eosinophils — research and specialized centers; eosinophils >2 percent indicates eosinophilic asthma; (e) Other emerging — periostin, DPP-4, Th2 chemokines, microbiome.

Six asthma biologics currently FDA-approved each targeting different inflammatory pathway: (1) Omalizumab (Xolair) — anti-IgE monoclonal antibody (2003); (2) Mepolizumab (Nucala) — anti-IL-5 (2015); (3) Reslizumab (Cinqair) — anti-IL-5 (2016); (4) Benralizumab (Fasenra) — anti-IL-5 receptor α with afucosylated Fc enhancing eosinophil ADCC (2017); (5) Dupilumab (Dupixent) — anti-IL-4 receptor α blocking both IL-4 and IL-13 signaling (2018 for asthma); (6) Tezepelumab (Tezspire) — anti-TSLP (2021). Selection requires consideration of asthma endotype, biomarkers, comorbidities, prior treatments, dosing preference, and cost.

Symptoms

Severe asthma uncontrolled despite high-dose ICS plus LABA/LAMA
Frequent severe exacerbations (≥2 per year requiring oral corticosteroids)
Hospitalization or ICU admission for asthma exacerbation
Oral corticosteroid dependence with significant cumulative exposure
Persistent airflow obstruction with FEV1 <80 percent predicted post-bronchodilator
High symptom burden with poor quality of life despite controller therapy
Concurrent atopic comorbidities — allergic rhinitis, CRSwNP, atopic dermatitis, eosinophilic esophagitis
Adverse effects of high-dose ICS or chronic OCS (osteoporosis, diabetes, weight gain, cataracts, cushingoid features)
T2-high biomarker pattern (eos ≥300 cells/μL, FeNO ≥25 ppb, atopic with elevated IgE)
T2-low biomarker pattern (eos <300 cells/μL, FeNO <25 ppb, neutrophilic or paucigranulocytic)

Risk Factors

Severe asthma criteria fulfilled (high-dose ICS-LABA, OCS-dependent, frequent exacerbations)
Genetic predisposition (asthma family history, atopic comorbidities)
Environmental exposures (allergens, viruses, pollutants, smoke, occupational irritants)
Comorbidities affecting asthma control (obesity, GERD, allergic rhinitis, CRSwNP, OSA, smoking)
Failure of conventional asthma therapy escalation (steps 4-5 GINA)
Specific biomarker patterns guiding biologic selection
Prior biologic failure with persistent disease (consider switch class)
Adverse effects of corticosteroids requiring OCS-sparing strategy
Pregnancy or planning (limited biologic safety data; tezepelumab least studied)
Live vaccine plans (avoid during biologic therapy)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Severe asthma uncontrolled despite optimal step 4-5 GINA therapy
  • Frequent exacerbations or OCS dependence
  • Need for biologic candidacy assessment
  • Comprehensive severe asthma center evaluation
  • Failure of one biologic — assessment for switching to different class
  • Comorbid CRSwNP-AD-EGPA-eosinophilic esophagitis (consider dupilumab; mepolizumab for EGPA)
  • T2-low or low eosinophil severe asthma (tezepelumab indication)
  • Pregnancy planning while on biologic — risk-benefit discussion
  • OCS side effects requiring OCS-sparing biologic
  • Acute severe asthma exacerbation despite biologic — emergency department

Treatment Methods

01
Step 1 — Confirm severe asthma diagnosis: confirm asthma diagnosis (objective testing — spirometry with bronchodilator reversibility >12 percent and 200 mL FEV1 increase, or methacholine challenge with PC20 <16 mg/mL for borderline cases), exclude alternative diagnoses (vocal cord dysfunction, ABPA, EGPA, bronchiectasis, COPD, cardiac asthma, hyperventilation), assess GINA control level (well-controlled, partly controlled, uncontrolled), document exacerbation frequency over past year, OCS use and cumulative dose, current controller therapy and adherence, inhaler technique
02
Step 2 — Optimize controller therapy: ensure high-dose ICS-LABA combination (high dose >500 mcg fluticasone propionate equivalent), add LAMA (tiotropium) for partial response, leukotriene receptor antagonist (montelukast) per indication, theophylline if needed, address adherence (objective measurement preferred), inhaler technique (spacer for MDI, train on dry powder devices), trigger avoidance (allergens, smoke, irritants, occupational), comorbidity management (allergic rhinitis with intranasal steroids, CRSwNP, GERD, OSA, obesity, smoking cessation)
03
Step 3 — Phenotype and endotype workup: blood eosinophil count (recent within 1–6 months, may need to repeat off OCS as steroids suppress eos), serum total IgE and specific aeroallergen IgE or skin prick testing, FeNO if available (off ICS for accurate baseline impractical, consider during stable phase), sputum induction if specialized center available, chest CT if not recently done (assess for bronchiectasis, ABPA features, alternative diagnoses), assessment for AERD (history of NSAID-induced bronchospasm) and EGPA (peripheral neuropathy, vasculitis features)
04
Step 4 — Biologic selection algorithm: (A) T2-high allergic asthma with elevated IgE 30–700 IU/mL and aeroallergen sensitization → omalizumab first-line (long safety record, oldest); (B) T2-high eosinophilic asthma with eos ≥300 cells/μL → mepolizumab, reslizumab, or benralizumab (anti-IL-5 class); benralizumab favored for very high eos, prior eosinophilic exacerbations; (C) T2 mixed asthma with eos ≥150 cells/μL OR FeNO ≥25 ppb, especially with comorbid CRSwNP or atopic dermatitis → dupilumab; very effective for these comorbidities; (D) Severe asthma regardless of phenotype, especially T2-low (eos <300, FeNO <25), or after biologic failure → tezepelumab (anti-TSLP — only biologic without biomarker requirement); (E) EGPA with asthma — mepolizumab approved specifically for EGPA at 300 mg SC monthly; (F) OCS-dependent severe asthma — all biologics may help; tezepelumab (SOURCE), benralizumab (PONENTE), mepolizumab (SIRIUS), dupilumab have demonstrated significant OCS-sparing effects; choose by biomarker profile
05
Pre-biologic checklist: confirm severe asthma criteria, biomarker workup complete, vaccinations updated (avoid live vaccines starting), pregnancy testing in women, helminth screening if endemic, baseline lung function and symptom scores, clear treatment goals discussed (target PASI/asthma control improvement, exacerbation reduction, OCS sparing, lung function gain)
06
Initiation and monitoring: start chosen biologic at standard dose; first administration in clinic for monitoring; assess at 3–6 months for: symptom improvement (ACT increase ≥3 points or ACQ-6 decrease ≥0.5), exacerbation reduction (significant reduction expected), lung function improvement, OCS dose reduction in OCS-dependent; document response in registry
07
Switching biologics: indications include primary non-response (<3 months no improvement), secondary loss of response, adverse events, comorbidity development requiring different mechanism; switching strategies — within-class switch (e.g., mepolizumab to benralizumab — limited evidence, often less effective than across class), across-class switch (e.g., anti-IL-5 to dupilumab or tezepelumab — often more effective); no washout period typically required (start new at next planned dose); document reason for switch
08
Special populations: (1) Pregnancy — uncontrolled asthma during pregnancy is high-risk for both mother and fetus; biologics with most reassuring safety data: omalizumab (registry data), mepolizumab and dupilumab (limited but reassuring); tezepelumab limited data; risk-benefit discussion essential; preferred to maintain control; (2) Adolescents — ages 6+ omalizumab, ages 12+ mepolizumab, dupilumab, tezepelumab; (3) Elderly — generally safe at standard doses, attention to comorbidities and polypharmacy; (4) Smokers — biologic efficacy may be reduced; smoking cessation paramount
09
Comorbidity-driven selection: CRSwNP — dupilumab is FDA-approved for CRSwNP at higher dose 300 mg every 2 weeks (versus asthma 200 mg); omalizumab also approved for CRSwNP; atopic dermatitis — dupilumab strongly preferred (FDA-approved for AD); eosinophilic esophagitis — dupilumab approved; CSU (chronic spontaneous urticaria) — omalizumab; EGPA — mepolizumab approved; aspirin-exacerbated respiratory disease (AERD) — dupilumab and aspirin desensitization combination
10
Adjunctive measures: continue ICS-LABA (do not discontinue with biologic), maintain other controllers as tolerated, gradual OCS taper after stable response, lifestyle modifications (smoking cessation, weight management, exercise within tolerance), sinus and AD treatment, asthma action plan with biologic incorporated, vaccinations (inactivated influenza annually, COVID-19, pneumococcal PCV13/PPSV23, complete childhood vaccinations before initiation; no live vaccines)
11
Long-term: indefinite continuation while providing benefit; periodic reassessment for need (controversial whether to discontinue after sustained remission); patient education on injection technique, sharps disposal, signs to seek medical attention, missed dose strategy; multidisciplinary care (severe asthma specialist, pulmonologist, allergist-immunologist, primary care, ENT, sleep medicine, mental health for depression-anxiety associated with severe disease)

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.